CANAGLIFLOZIN

Course overview

CANAGLIFLOZIN IS AN ORAL C-GLYCOSYL COMPOUND ANTIHYPERGLYCEMIC AGENT. SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) IS EXPRESSED ON THE PROXIMAL RENAL TUBULES AND IS PRIMARILY RESPONSIBLE FOR THE REABSORPTION OF 90% OF THE GLUCOSE FILTERED BY OUR KIDNEYS. CANAGLIFLOZIN INHIBITS THE PROXIMAL RENAL TUBULES' SGLT2 RECEPTORS. THIS ACTION DECREASES RENAL GLUCOSE ABSORPTION AND THE RENAL THRESHOLD FOR GLUCOSE AND INCREASES URINARY EXCRETION. CANAGLIFLOZIN WAS APPROVED IN 2013 BY THE FOOD AND DRUG ADMINISTRATION (FDA). CANAGLIFLOZIN IS UTILIZED TO TREAT PATIENTS WHO ARE DIAGNOSED WITH TYPE 2 DIABETES MELLITUS (T2DM) AND OTHER DISEASE STATES WITH EITHER APPROVED OR NON-FDA-APPROVED INDICATIONS. THIS ACTIVITY FOCUSES ON THE INDICATIONS, CONTRAINDICATIONS, MECHANISM OF ACTION, ADVERSE EFFECTS, AND OTHER CRITICAL FEATURES OF CANAGLIFLOZIN. INCORPORATING CONSIDERATIONS FOR SPECIAL POPULATIONS, SUCH AS PREGNANCY, LACTATION, AND RENAL OR HEPATIC IMPAIRMENT, STRENGTHENS THE IMPLEMENTATION OF SAFE PRESCRIBING PRACTICES. THIS COMPREHENSIVE EDUCATIONAL ACTIVITY AIMS TO PROMOTE PROFICIENCY IN UTILIZING THIS KNOWLEDGE TO MAXIMIZE MEDICATION EFFICACY AND MINIMIZE THE RISK OF ADVERSE DRUG EVENTS.